Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Colorectal Neoplasms

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 128 articles:
HTML format
Text format



Single Articles


    May 2018
  1. ZUNDER SM, van Pelt GW, Gelderblom HJ, Mancao C, et al
    Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0083.
    PubMed     Text format     Abstract available


  2. MA R, Xu L, Qu X, Che X, et al
    AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0086.
    PubMed     Text format     Abstract available


    April 2018
  3. BERGHEIM J, Semaan A, Gevensleben H, Groening S, et al
    Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study.
    Br J Cancer. 2018 Apr 3. pii: 10.1038/s41416-018-0035.
    PubMed     Text format     Abstract available


    March 2018
  4. SHINOZAKI E, Yoshino T, Tsuchihara K
    Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Ant
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0040.
    PubMed     Text format    


  5. DANKNER M, Rose AAN
    Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by
    Br J Cancer. 2018 Mar 22. pii: 10.1038/s41416-018-0012.
    PubMed     Text format    


  6. CREMOLINI C, Milione M, Marmorino F, Morano F, et al
    Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.
    Br J Cancer. 2018 Mar 13. pii: 10.1038/s41416-018-0015.
    PubMed     Text format     Abstract available


  7. MORRIS JS, Bradbury KE, Cross AJ, Gunter MJ, et al
    Physical activity, sedentary behaviour and colorectal cancer risk in the UK Biobank.
    Br J Cancer. 2018 Mar 8. pii: bjc2017496. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2018
  8. USHER-SMITH JA, Harshfield A, Saunders CL, Sharp SJ, et al
    External validation of risk prediction models for incident colorectal cancer using UK Biobank.
    Br J Cancer. 2018 Jan 30. pii: bjc2017463. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  9. TAPIAL S, Rueda D, Arriba M, Luis Garcia J, et al
    Comment on 'Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system'.
    Br J Cancer. 2018 Jan 2. pii: bjc2017343. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  10. FENG H, Zhao JK, Schiergens TS, Wang PX, et al
    Bone marrow-derived mesenchymal stromal cells promote colorectal cancer cell death under low-dose irradiation.
    Br J Cancer. 2018 Jan 2. pii: bjc2017415. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  11. BAE JM, Kim JH, Kwak Y, Lee DW, et al
    Reply to 'Comment on 'Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system".
    Br J Cancer. 2018 Jan 2. pii: bjc2017426. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    December 2017
  12. KIM SR, Song N, Yothers G, Gavin PG, et al
    Tumour sidedness and intrinsic subtypes in patients with stage II/III colon cancer: analysis of NSABP C-07 (NRG Oncology).
    Br J Cancer. 2017 Dec 14. pii: bjc2017448. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  13. FENG H, Liu Y, Bian X, Zhou F, et al
    ALDH1A3 affects colon cancer in vitro proliferation and invasion depending on CXCR4 status.
    Br J Cancer. 2017 Dec 12. pii: bjc2017363. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  14. DOPESO H, Rodrigues P, Bilic J, Bazzocco S, et al
    Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer.
    Br J Cancer. 2017 Dec 5. pii: bjc2017420. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  15. ALBUQUERQUE A, Pessegueiro Miranda H, Lopes J, Gandara J, et al
    Liver transplant recipients have a higher prevalence of anal squamous intraepithelial lesions.
    Br J Cancer. 2017;117:1761-1767.
    PubMed     Text format     Abstract available


  16. LIEVRE A, Ouine B, Canet J, Cartier A, et al
    Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma.
    Br J Cancer. 2017;117:1819-1827.
    PubMed     Text format     Abstract available


    November 2017
  17. PILLOZZI S, D'Amico M, Bartoli G, Gasparoli L, et al
    The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells.
    Br J Cancer. 2017 Nov 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  18. FLOUD S, Barnes I, Verfurden M, Kuper H, et al
    Disability and participation in breast and bowel cancer screening in England: a large prospective study.
    Br J Cancer. 2017;117:1711-1714.
    PubMed     Text format     Abstract available


  19. GOEL A
    IGF-1R: SUMO-ing its weight in chemoresistant colorectal cancer.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  20. CODONY-SERVAT J, Cuatrecasas M, Asensio E, Montironi C, et al
    Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  21. GOEY KKH, Elias SG, Hinke A, van Oijen MGH, et al
    Clinicopathological factors influencing outcome in metastatic colorectal cancer patients treated with fluoropyrimidine and bevacizumab maintenance treatment vs observation: an individual patient data meta-analysis of two phase 3 trials.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  22. SCLAFANI F, Brown G, Cunningham D, Wotherspoon A, et al
    Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer.
    Br J Cancer. 2017;117:1478-1485.
    PubMed     Text format     Abstract available


  23. COOPER JA, Parsons N, Stinton C, Mathews C, et al
    Risk-adjusted colorectal cancer screening using the FIT and routine screening data: development of a risk prediction model.
    Br J Cancer. 2017 Nov 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    October 2017
  24. MURAKAMI T, Kikuchi H, Ishimatsu H, Iino I, et al
    Tenascin C in colorectal cancer stroma is a predictive marker for liver metastasis and is a potent target of miR-198 as identified by microRNA analysis.
    Br J Cancer. 2017;117:1360-1370.
    PubMed     Text format     Abstract available


  25. RUZZO A, Graziano F, Galli F, Galli F, et al
    Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
    Br J Cancer. 2017;117:1269-1277.
    PubMed     Text format     Abstract available


  26. HOU L, Zhu D, Liang Y, Tian X, et al
    Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  27. THERKILDSEN C, Ladelund S, Smith-Hansen L, Lindberg LJ, et al
    Towards gene- and gender-based risk estimates in Lynch syndrome; age-specific incidences for 13 extra-colorectal cancer types.
    Br J Cancer. 2017 Oct 24. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  28. GOLLINS S, West N, Sebag-Montefiore D, Myint AS, et al
    Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations.
    Br J Cancer. 2017;117:1286-1294.
    PubMed     Text format     Abstract available


  29. LETELLIER E, Schmitz M, Ginolhac A, Rodriguez F, et al
    Loss of Myosin Vb in colorectal cancer is a strong prognostic factor for disease recurrence.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  30. SHINOZAKI E, Yoshino T, Yamazaki K, Muro K, et al
    Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensi
    Br J Cancer. 2017 Oct 3. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  31. GAYARRE J, Martin-Gimeno P, Osorio A, Paumard B, et al
    Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.
    Br J Cancer. 2017;117:1048-1062.
    PubMed     Text format     Abstract available


  32. BROWN JC, Zemel BS, Troxel AB, Rickels MR, et al
    Dose-response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial.
    Br J Cancer. 2017 Sep 21. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  33. GIAMPIERI R, Puzzoni M, Daniele B, Ferrari D, et al
    First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) tr
    Br J Cancer. 2017 Sep 19. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  34. MATSUMOTO A, Arcaroli J, Chen Y, Gasparetto M, et al
    Aldehyde dehydrogenase 1B1: a novel immunohistological marker for colorectal cancer.
    Br J Cancer. 2017 Sep 7. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  35. SCHUBERT SA, Ruano D, Elsayed FA, Boot A, et al
    Evidence for genetic association between chromosome 1q loci and predisposition to colorectal neoplasia.
    Br J Cancer. 2017;117:876-884.
    PubMed     Text format     Abstract available


    August 2017
  36. FOWLER H, Belot A, Njagi EN, Luque-Fernandez MA, et al
    Persistent inequalities in 90-day colon cancer mortality: an English cohort study.
    Br J Cancer. 2017 Aug 31. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  37. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Text format     Abstract available


  38. ALLARD MA, Adam R, Giuliante F, Lapointe R, et al
    Long-term outcomes of patients with 10 or more colorectal liver metastases.
    Br J Cancer. 2017;117:604-611.
    PubMed     Text format     Abstract available


  39. LEVI F, Karaboue A, Saffroy R, Desterke C, et al
    Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  40. YUAN C, Bao Y, Sato K, Nimptsch K, et al
    Influence of dietary insulin scores on survival in colorectal cancer patients.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  41. YANG SS, Li XM, Yang M, Ren XL, et al
    FMNL2 destabilises COMMD10 to activate NF-kappaB pathway in invasion and metastasis of colorectal cancer.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  42. YUAN Z, Baker K, Redman MW, Wang L, et al
    Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.
    Br J Cancer. 2017 Aug 15. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  43. TORRING ML, Murchie P, Hamilton W, Vedsted P, et al
    Evidence of advanced stage colorectal cancer with longer diagnostic intervals: a pooled analysis of seven primary care cohorts comprising 11 720 patients in five countries.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  44. ZHU Y, Wang PP, Zhai G, Bapat B, et al
    Vitamin D receptor and calcium-sensing receptor polymorphisms and colorectal cancer survival in the Newfoundland population.
    Br J Cancer. 2017 Aug 1. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    July 2017
  45. BHATTACHARYA R, Fan F, Wang R, Ye X, et al
    Intracrine VEGF signalling mediates colorectal cancer cell migration and invasion.
    Br J Cancer. 2017 Jul 25. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  46. WALKER AK, Kartsonaki C, Collantes E, Nicholson J, et al
    No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy.
    Br J Cancer. 2017;117:322-325.
    PubMed     Text format     Abstract available


  47. KNUDSEN MD, Berstad P, Hjartaker A, Gulichsen EH, et al
    Lifestyle predictors for non-participation and outcome in the second round of faecal immunochemical test in colorectal cancer screening.
    Br J Cancer. 2017 Jul 13. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  48. GASH KJ, Chambers AC, Cotton DE, Williams AC, et al
    Potentiating the effects of radiotherapy in rectal cancer: the role of aspirin, statins and metformin as adjuncts to therapy.
    Br J Cancer. 2017;117:210-219.
    PubMed     Text format     Abstract available


  49. ALONSO MH, Ausso S, Lopez-Doriga A, Cordero D, et al
    Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    June 2017
  50. LIAO Q, Li R, Zhou R, Pan Z, et al
    LIM kinase 1 interacts with myosin-9 and alpha-actinin-4 and promotes colorectal cancer progression.
    Br J Cancer. 2017 Jun 29. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  51. ODDO D, Siravegna G, Gloghini A, Vernieri C, et al
    Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
    Br J Cancer. 2017 Jun 27. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  52. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Text format     Abstract available


  53. CHAKRABARTY S, Varghese VK, Sahu P, Jayaram P, et al
    Targeted sequencing-based analyses of candidate gene variants in ulcerative colitis-associated colorectal neoplasia.
    Br J Cancer. 2017;117:136-143.
    PubMed     Text format     Abstract available


  54. HATA T, Takemasa I, Takahashi H, Haraguchi N, et al
    Downregulation of serum metabolite GTA-446 as a novel potential marker for early detection of colorectal cancer.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  55. VAN EGGERMOND AM, Schaapveld M, Janus CP, de Boer JP, et al
    Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  56. DEMURTAS L, Puzzoni M, Giampieri R, Ziranu P, et al
    The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  57. MARIANI S, Bertero L, Osella-Abate S, Di Bello C, et al
    Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene.
    Br J Cancer. 2017 Jun 15. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  58. ALVI MA, Loughrey MB, Dunne P, McQuaid S, et al
    Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies.
    Br J Cancer. 2017 Jun 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  59. BENTON SC, Butler P, Allen K, Chesters M, et al
    GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project.
    Br J Cancer. 2017;116:1551-1557.
    PubMed     Text format     Abstract available


  60. SIDDIQUI MRS, Simillis C, Hunter C, Chand M, et al
    A meta-analysis comparing the risk of metastases in patients with rectal cancer and MRI-detected extramural vascular invasion (mrEMVI) vs mrEMVI-negative cases.
    Br J Cancer. 2017;116:1513-1519.
    PubMed     Text format     Abstract available


    May 2017
  61. ALNABULSI A, Swan R, Cash B, Alnabulsi A, et al
    The differential expression of omega-3 and omega-6 fatty acid metabolising enzymes in colorectal cancer and its prognostic significance.
    Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  62. FREISLING H, Arnold M, Soerjomataram I, O'Doherty MG, et al
    Comparison of general obesity and measures of body fat distribution in older adults in relation to cancer risk: meta-analysis of individual participant data of seven prospective cohorts in Europe.
    Br J Cancer. 2017;116:1486-1497.
    PubMed     Text format     Abstract available


  63. GRAY RT, Loughrey MB, Bankhead P, Cardwell CR, et al
    Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.
    Br J Cancer. 2017 May 18. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  64. MOUNCE LTA, Price S, Valderas JM, Hamilton W, et al
    Comorbid conditions delay diagnosis of colorectal cancer: a cohort study using electronic primary care records.
    Br J Cancer. 2017 May 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  65. DYER KE, Dumenci L, Siminoff LA, Thomson MD, et al
    The contribution of body mass index to appraisal delay in colorectal cancer diagnosis: a structural equation modelling study.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  66. HIRST Y, Skrobanski H, Kerrison RS, Kobayashi LC, et al
    Text-message Reminders in Colorectal Cancer Screening (TRICCS): a randomised controlled trial.
    Br J Cancer. 2017 Apr 25. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  67. CALEGARI MA, Inno A, Monterisi S, Orlandi A, et al
    A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  68. PARK JH, van Wyk H, Roxburgh CSD, Horgan PG, et al
    Tumour invasiveness, the local and systemic environment and the basis of staging systems in colorectal cancer.
    Br J Cancer. 2017 Apr 20. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  69. GUREN TK, Thomsen M, Kure EH, Sorbye H, et al
    Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.
    Br J Cancer. 2017 Apr 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  70. YOKOI K, Yamashita K, Ishii S, Tanaka T, et al
    Comprehensive molecular exploration identified promoter DNA methylation of the CRBP1 gene as a determinant of radiation sensitivity in rectal cancer.
    Br J Cancer. 2017;116:1046-1056.
    PubMed     Text format     Abstract available


  71. GHUMAN S, Van Hemelrijck M, Garmo H, Holmberg L, et al
    Serum inflammatory markers and colorectal cancer risk and survival.
    Br J Cancer. 2017 Apr 4. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    March 2017
  72. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Text format     Abstract available


  73. FURLAN D, Trapani D, Berrino E, Debernardi C, et al
    Oxidative DNA damage induces hypomethylation in a compromised base excision repair colorectal tumourigenesis.
    Br J Cancer. 2017;116:793-801.
    PubMed     Text format     Abstract available


  74. BAE JM, Kim JH, Kwak Y, Lee DW, et al
    Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system.
    Br J Cancer. 2017 Mar 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  75. GOSHEN R, Mizrahi B, Akiva P, Kinar Y, et al
    Predicting the presence of colon cancer in members of a health maintenance organisation by evaluating analytes from standard laboratory records.
    Br J Cancer. 2017 Mar 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    February 2017
  76. SCHIFFMANN LM, Brunold M, Liwschitz M, Goede V, et al
    A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition.
    Br J Cancer. 2017;116:600-608.
    PubMed     Text format     Abstract available


  77. JONES RP, Sutton PA, Evans JP, Clifford R, et al
    Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  78. LECLERC D, Pham DN, Levesque N, Truongcao M, et al
    Oncogenic role of PDK4 in human colon cancer cells.
    Br J Cancer. 2017 Feb 16. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  79. ENGLINGER B, Mair M, Miklos W, Pirker C, et al
    Loss of CUL4A expression is underlying cisplatin hypersensitivity in colorectal carcinoma cells with acquired trabectedin resistance.
    Br J Cancer. 2017;116:489-500.
    PubMed     Text format     Abstract available


  80. CARTER JV, Galbraith NJ, Yang D, Burton JF, et al
    Blood-based microRNAs as biomarkers for the diagnosis of colorectal cancer: a systematic review and meta-analysis.
    Br J Cancer. 2017 Feb 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  81. HU H, Shu M, He L, Yu X, et al
    Epigenomic landscape of 5-hydroxymethylcytosine reveals its transcriptional regulation of lncRNAs in colorectal cancer.
    Br J Cancer. 2017 Jan 31. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  82. CREAVIN B, Ryan E, Martin ST, Hanly A, et al
    Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer.
    Br J Cancer. 2017;116:169-174.
    PubMed     Text format     Abstract available


  83. JONES CM, Goh V, Sebag-Montefiore D, Gilbert DC, et al
    Biomarkers in anal cancer: from biological understanding to stratified treatment.
    Br J Cancer. 2017;116:156-162.
    PubMed     Text format     Abstract available


  84. MARMORINO F, Salvatore L, Barbara C, Allegrini G, et al
    Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
    Br J Cancer. 2017;116:318-323.
    PubMed     Text format     Abstract available


  85. AQUINA CT, Mohile SG, Tejani MA, Becerra AZ, et al
    The impact of age on complications, survival, and cause of death following colon cancer surgery.
    Br J Cancer. 2017 Jan 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    December 2016
  86. CRISTOBAL I, Torrejon B, Madoz-Gurpide J, Rojo F, et al
    Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.
    Br J Cancer. 2016 Dec 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  87. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    Reply: Comment on 'MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells'.
    Br J Cancer. 2016 Dec 20. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  88. VAN DER VLUGT M, Grobbee EJ, Bossuyt PM, Bongers E, et al
    Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening.
    Br J Cancer. 2016 Dec 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  89. RENNERT G
    Reproductive factors, hormones and colorectal cancer-still unresolved.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  90. MURPHY N, Xu L, Zervoudakis A, Xue X, et al
    Reproductive and menstrual factors and colorectal cancer incidence in the Women's Health Initiative Observational Study.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  91. DE SMEDT L, Palmans S, Andel D, Govaere O, et al
    Expression profiling of budding cells in colorectal cancer reveals an EMT-like phenotype and molecular subtype switching.
    Br J Cancer. 2016 Nov 24. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  92. DEN UIL SH, Coupe VM, Linnekamp JF, van den Broek E, et al
    Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.
    Br J Cancer. 2016 Nov 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  93. HE GY, Hu JL, Zhou L, Zhu XH, et al
    The FOXD3/miR-214/MED19 axis suppresses tumour growth and metastasis in human colorectal cancer.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  94. JIA M, Jansen L, Walter V, Tagscherer K, et al
    No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
    Br J Cancer. 2016 Nov 3. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  95. MOSKAL A, Freisling H, Byrnes G, Assi N, et al
    Main nutrient patterns and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  96. KARTHAUS M, Hofheinz RD, Mineur L, Letocha H, et al
    Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  97. BLINMAN P, Mileshkin L, Khaw P, Goss G, et al
    Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  98. KIM TW, Elme A, Kusic Z, Park JO, et al
    A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.
    Br J Cancer. 2016 Oct 13. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  99. MARZI L, Combes E, Vie N, Ayrolles-Torro A, et al
    FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
    Br J Cancer. 2016 Sep 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  100. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  101. ROGERS AC, Winter DC, Heeney A, Gibbons D, et al
    Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer.
    Br J Cancer. 2016 Sep 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    August 2016
  102. FARSHIDFAR F, Weljie AM, Kopciuk KA, Hilsden R, et al
    A validated metabolomic signature for colorectal cancer: exploration of the clinical value of metabolomics.
    Br J Cancer. 2016 Aug 25. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  103. RENZI C, Lyratzopoulos G, Card T, Chu TP, et al
    Do colorectal cancer patients diagnosed as an emergency differ from non-emergency patients in their consultation patterns and symptoms? A longitudinal data-linkage study in England.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  104. CHANDRASEKARAN KS, Sathyanarayanan A, Karunagaran D
    MicroRNA-214 suppresses growth, migration and invasion through a novel target, high mobility group AT-hook 1, in human cervical and colorectal cancer cells.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  105. ROSATO V, Guercio V, Bosetti C, Negri E, et al
    Mediterranean diet and colorectal cancer risk: a pooled analysis of three Italian case-control studies.
    Br J Cancer. 2016 Aug 18. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  106. LIGI D, Mannello F
    Do matrix metalloproteinases represent reliable circulating biomarkers in colorectal cancer?
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    PubMed     Text format    


  107. BEALE G, Haagensen EJ, Thomas HD, Wang LZ, et al
    Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo antitumour activity in colorectal cancer.
    Br J Cancer. 2016 Aug 16. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  108. WALTER FM, Emery JD, Mendonca S, Hall N, et al
    Symptoms and patient factors associated with longer time to diagnosis for colorectal cancer: results from a prospective cohort study.
    Br J Cancer. 2016 Aug 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    July 2016
  109. DREWES JL, Housseau F, Sears CL
    Sporadic colorectal cancer: microbial contributors to disease prevention, development and therapy.
    Br J Cancer. 2016 Jul 5. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    June 2016
  110. JARVIS D, Mitchell JS, Law PJ, Palin K, et al
    Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  111. STAFF S, Aaltonen M, Huhtala H, Pylvanainen K, et al
    Endometrial cancer risk factors among Lynch syndrome women: a retrospective cohort study.
    Br J Cancer. 2016 Jun 23. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  112. PILERI P, Campagnoli S, Grandi A, Parri M, et al
    FAT1: a potential target for monoclonal antibody therapy in colon cancer.
    Br J Cancer. 2016 Jun 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  113. BENITEZ-MAJANO S, Fowler H, Maringe C, Di Girolamo C, et al
    Deriving stage at diagnosis from multiple population-based sources: colorectal and lung cancer in England.
    Br J Cancer. 2016 Jun 21. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  114. CHA Y, Kim KJ, Han SW, Rhee YY, et al
    Adverse prognostic impact of the CpG island methylator phenotype in metastatic colorectal cancer.
    Br J Cancer. 2016 Jun 16. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  115. VAN WYK HC, Park JH, Edwards J, Horgan PG, et al
    The relationship between tumour budding, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
    Br J Cancer. 2016 Jun 14. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  116. KONDO T, Okabayashi K, Hasegawa H, Tsuruta M, et al
    The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer.
    Br J Cancer. 2016 Jun 9. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  117. LEE MS, McGuffey EJ, Morris JS, Manyam G, et al
    Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer.
    Br J Cancer. 2016 Jun 7. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    May 2016
  118. VAYRYNEN SA, Vayrynen JP, Klintrup K, Makela J, et al
    Clinical impact and network of determinants of tumour necrosis in colorectal cancer.
    Br J Cancer. 2016 May 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    April 2016
  119. JOHNSON SP, Ramasawmy R, Campbell-Washburn AE, Wells JA, et al
    Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling.
    Br J Cancer. 2016;114:897-904.
    PubMed     Text format     Abstract available


    March 2016
  120. POTTEGARD A, Ennis ZN, Hallas J, Jensen BL, et al
    Long-term use of lithium and risk of colorectal adenocarcinoma: a nationwide case-control study.
    Br J Cancer. 2016;114:571-5.
    PubMed     Text format     Abstract available


    February 2016
  121. MAX N, Harbaum L, Pollheimer MJ, Lindtner RA, et al
    Tumour budding with and without admixed inflammation: two different sides of the same coin?
    Br J Cancer. 2016;114:368-71.
    PubMed     Text format     Abstract available


  122. LOMAKINA ME, Lallemand F, Vacher S, Molinie N, et al
    Arpin downregulation in breast cancer is associated with poor prognosis.
    Br J Cancer. 2016 Feb 11. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  123. MARSHALL DC, Webb TE, Hall RA, Salciccioli JD, et al
    Trends in UK regional cancer mortality 1991-2007.
    Br J Cancer. 2016;114:340-7.
    PubMed     Text format     Abstract available


  124. KEARNS B, Whyte S, Seaman HE, Snowball J, et al
    Factors associated with completion of bowel cancer screening and the potential effects of simplifying the screening test algorithm.
    Br J Cancer. 2016;114:327-33.
    PubMed     Text format     Abstract available


  125. RAINE R, Duffy SW, Wardle J, Solmi F, et al
    Impact of general practice endorsement on the social gradient in uptake in bowel cancer screening.
    Br J Cancer. 2016;114:321-6.
    PubMed     Text format     Abstract available


    January 2016
  126. KIM SA, Inamura K, Yamauchi M, Nishihara R, et al
    Loss of CDH1 (E-cadherin) expression is associated with infiltrative tumour growth and lymph node metastasis.
    Br J Cancer. 2016;114:199-206.
    PubMed     Text format     Abstract available


  127. GILBERT DC, Serup-Hansen E, Linnemann D, Hogdall E, et al
    Tumour-infiltrating lymphocyte scores effectively stratify outcomes over and above p16 post chemo-radiotherapy in anal cancer.
    Br J Cancer. 2016;114:134-7.
    PubMed     Text format     Abstract available


  128. KEUM N, Cao Y, Lee DH, Park SM, et al
    Male pattern baldness and risk of colorectal neoplasia.
    Br J Cancer. 2016;114:110-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: